Stereotactic Re-irradiation for Recurrence of Breast Cancer in Lymph Nodes - Summary - MDSpire

Stereotactic Re-irradiation for Recurrence of Breast Cancer in Lymph Nodes

  • By

  • Zied Fessi

  • Salomé Bonnier

  • Kaoutar Lodyga

  • Jennifer Wallet

  • Maël Barthoulot

  • Chloé Delerue

  • Pauline Lemoine

  • Paul Archer

  • Marie Dworczak

  • David Pasquier

  • December 8, 2025

  • 0 min

Share

Objective:

To evaluate the feasibility, toxicity profile, and clinical outcomes of stereotactic body radiotherapy (SBRT) for nodal recurrence in breast cancer.

Key Findings:
  • SBRT demonstrated feasibility for treating nodal recurrence in breast cancer.
  • Acute and late toxicities were assessed, with a focus on toxicity greater than grade 2.
  • Locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS) were evaluated.
Interpretation:

SBRT may be a viable option for managing nodal recurrences in breast cancer, with acceptable toxicity profiles.

Limitations:
  • Small sample size limits the generalizability of the findings.
  • Retrospective nature may introduce bias.
Conclusion:

SBRT shows promise for treating lymph node recurrences in breast cancer, warranting further investigation.

Original Source(s)

Stereotactic Re-irradiation for Recurrence of Breast Cancer in Lymph Nodes

  • by Zied Fessi, Salomé Bonnier, Kaoutar Lodyga, Jennifer Wallet, Maël Barthoulot, Chloé Delerue, Pauline Lemoine, Paul Archer, Marie Dworczak, David Pasquier

  • December 8, 2025

Related Content

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant